Short Interest in Genenta Science S.p.A. (NASDAQ:GNTA) Rises By 30.8%

Genenta Science S.p.A. (NASDAQ:GNTA) was the recipient of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 3,400 shares, a growth of 30.8% from the January 15th total of 2,600 shares. Based on an average daily volume of 10,600 shares, the short-interest ratio is currently 0.3 days.

Genenta Science Stock Performance

Shares of NASDAQ:GNTA traded up $0.55 during mid-day trading on Friday, reaching $4.37. 6,022 shares of the company were exchanged, compared to its average volume of 10,297. The firm’s 50-day simple moving average is $4.46 and its 200 day simple moving average is $4.59. Genenta Science has a 1 year low of $2.20 and a 1 year high of $7.28.

Hedge Funds Weigh In On Genenta Science

An institutional investor recently bought a new position in Genenta Science stock. Allianz SE purchased a new stake in Genenta Science S.p.A. (NASDAQ:GNTA) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 103,250 shares of the company’s stock, valued at approximately $444,000. Allianz SE owned 0.56% of Genenta Science as of its most recent SEC filing. 15.13% of the stock is currently owned by hedge funds and other institutional investors.

Genenta Science Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.